{"id":5380,"date":"2014-11-24T12:09:26","date_gmt":"2014-11-24T17:09:26","guid":{"rendered":"https:\/\/themedicalxchange.com\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/"},"modified":"2021-09-07T11:34:00","modified_gmt":"2021-09-07T15:34:00","slug":"congres-scientifique-de-lamerican-heart-associat-2","status":"publish","type":"post","link":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/","title":{"rendered":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e"},"content":{"rendered":"<h2>D\u00e9termination des possibilit\u00e9s de traitement chez les patients ne tol\u00e9rant pas les statines<\/h2>\n<p>Le pourcentage de patients qualifi\u00e9s d\u2019intol\u00e9rants aux statines peut aller jusqu\u2019\u00e0 25\u00a0%. Or le D<sup>r<\/sup>\u00a0Patrick M. Moriarty, du Centre m\u00e9dical de l\u2019Universit\u00e9 du Kansas, \u00e0 Kansas City, chercheur principal et rapporteur de l\u2019essai ODYSSEY ALTERNATIVE, est d\u2019avis que plus de 50\u00a0% des patients dirig\u00e9s vers sa clinique le sont pour cause d\u2019intol\u00e9rance aux statines. \u00ab\u00a0Il s\u2019agit d\u2019une population de patients tr\u00e8s complexe, diversifi\u00e9e et qui se voit dans toutes les pratiques, a-t-il pr\u00e9cis\u00e9. Malheureusement, aucun essai d\u2019envergure, rigoureusement contr\u00f4l\u00e9 et men\u00e9 avec r\u00e9partition al\u00e9atoire des sujets n\u2019a port\u00e9 sur l\u2019utilisation de m\u00e9dicaments hypocholest\u00e9rol\u00e9miants chez ce type de patients. L\u2019alirocumab, un inhibiteur de la PCSK9 exp\u00e9rimental, pourrait \u00eatre extr\u00eamement utile \u00e0 ces patients au bout du compte\u00a0\u00bb, a ajout\u00e9 le D<sup>r<\/sup>\u00a0Moriarty.<\/p>\n<h2>Essai ODYSSEY ALTERNATIVE<\/h2>\n<p>Les chercheurs de l\u2019essai multicentrique international ODYSSEY ALTERNATIVE se sont pench\u00e9s sur l\u2019intol\u00e9rance aux statines, un probl\u00e8me qui prive beaucoup de patients de ces m\u00e9dicaments et les emp\u00eache d\u2019atteindre la valeur fix\u00e9e pour leur concentration de C-LDL. Pour ce faire, ils ont compar\u00e9 l\u2019alirocumab \u00e0 l\u2019\u00e9z\u00e9timibe, qui est recommand\u00e9 comme solution de rechange pour les patients qui ne supportent pas les statines en raison de sympt\u00f4mes musculaires (essai de deux statines, dont une \u00e0 la dose la plus faible recommand\u00e9e). L\u2019intol\u00e9rance aux statines a \u00e9t\u00e9 confirm\u00e9e au terme d\u2019une phase de 4\u00a0semaines avec un placebo suivie d\u2019un nouvel essai avec une statine. Au total, 314\u00a0patients atteints d\u2019une coronaropathie ou pr\u00e9sentant d\u2019autres facteurs de risque de maladie cardiovasculaire et incapables de tol\u00e9rer les statines ont \u00e9t\u00e9 r\u00e9partis au hasard de mani\u00e8re \u00e0 recevoir soit de l\u2019alirocumab \u00e0 75\u00a0mg par voie sous-cutan\u00e9e, qu\u2019ils s\u2019administraient eux-m\u00eames toutes les 2\u00a0semaines au moyen d\u2019un injecteur pr\u00e9rempli de 1\u00a0mL, soit de l\u2019\u00e9z\u00e9timibe \u00e0 10\u00a0mg\/jour, soit de l\u2019atorvastatine \u00e0 20\u00a0mg\/jour pendant 24\u00a0semaines. \u00c0 la 12<sup>e<\/sup>\u00a0semaine, la dose d\u2019alirocumab a \u00e9t\u00e9 port\u00e9e \u00e0 150\u00a0mg si le risque cardiovasculaire et la concentration de C-LDL mesur\u00e9e \u00e0 la 8<sup>e<\/sup>\u00a0semaine le justifiaient. Le D<sup>r<\/sup>\u00a0Moriarty a pr\u00e9cis\u00e9 que les concentrations de C-LDL de ces patients \u00e9taient extr\u00eamement \u00e9lev\u00e9es (de 4,91 \u00e0 5,02\u00a0mmol\/L\/jour) au d\u00e9part. Une forte proportion d\u2019entre eux pr\u00e9sentaient une hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote, un diab\u00e8te de type\u00a02 ou des ant\u00e9c\u00e9dents de coronaropathie. Or l\u2019analyse selon l\u2019intention de traiter r\u00e9alis\u00e9e \u00e0 la 24<sup>e<\/sup>\u00a0semaine a permis de constater que la baisse des concentrations de C-LDL, le param\u00e8tre d\u2019\u00e9valuation principal de cette \u00e9tude, \u00e9tait significativement plus marqu\u00e9e chez les patients trait\u00e9s par l\u2019alirocumab que chez ceux ayant pris de l\u2019\u00e9z\u00e9timibe (45,0\u00a0% vs 14,6\u00a0%; <em>p\u00a0<\/em>&lt;\u00a00,0001; <a href=\"javascript:void(0)\" class=\"show-image\" data-index=\"0\">(Fig. 1)<\/a>. L\u2019analyse des donn\u00e9es recueillies chez les patients trait\u00e9s, un important param\u00e8tre d\u2019\u00e9valuation secondaire, a fait ressortir des r\u00e9ductions respectives encore plus prononc\u00e9es (52,2\u00a0% vs 17,1\u00a0% <em>p\u00a0<\/em>&lt;\u00a00,0001). \u00ab\u00a0La diff\u00e9rence observ\u00e9e entre l\u2019effet exerc\u00e9 par l\u2019alirocumab et par l\u2019\u00e9z\u00e9timibe s\u2019est maintenue tout au long des 24\u00a0semaines.\u00a0\u00bb, a ajout\u00e9 le D<sup>r<\/sup>\u00a0Moriarty. Les sujets qui ont r\u00e9ussi \u00e0 atteindre la valeur vis\u00e9e pour leur concentration de C-LDL ont \u00e9t\u00e9 significativement plus nombreux dans le groupe trait\u00e9 par l\u2019alirocumab que dans celui ayant re\u00e7u de l\u2019\u00e9z\u00e9timibe (42\u00a0% vs 4\u00a0%, <em>p\u00a0<\/em>&lt;\u00a00,0001). \u00ab\u00a0D\u2019apr\u00e8s l\u2019analyse des sujets trait\u00e9s selon le protocole, ce pourcentage a exc\u00e9d\u00e9 les 50\u00a0% avec l\u2019alirocumab, alors que 6\u00a0% seulement des sujets trait\u00e9s par l\u2019\u00e9z\u00e9timibe ont atteint leur objectif\u00a0\u00bb, a affirm\u00e9 le D<sup>r<\/sup>\u00a0Moriarty. En outre, l\u2019alirocumab a \u00e9t\u00e9 mieux tol\u00e9r\u00e9 que l\u2019atorvastatine (RRI\u00a0: 1,63, <em>p\u00a0<\/em>=\u00a00,042), puisque l\u2019incidence des effets ind\u00e9sirables musculo-squelettiques qu\u2019il a provoqu\u00e9s a \u00e9t\u00e9 significativement plus faible (<em>p\u00a0<\/em>&lt;\u00a00,05). Pr\u00e8s de 80\u00a0% des patients soumis au processus de r\u00e9partition al\u00e9atoire ont particip\u00e9 \u00e0 une \u00e9tude de prolongation de 3\u00a0ans men\u00e9e en mode ouvert, durant laquelle ils ont tous re\u00e7u 75\u00a0mg d\u2019alirocumab toutes les 2\u00a0semaines (la dose pouvant \u00eatre port\u00e9e \u00e0 150\u00a0mg \u00e0 la 12<sup>e<\/sup>\u00a0semaine). \u00ab\u00a0\u00c0 52\u00a0semaines, 97\u00a0% des patients qui \u00e9taient totalement intol\u00e9rants aux statines ont \u00e9t\u00e9 capables de supporter l\u2019alirocumab\u00a0\u00bb, a d\u00e9clar\u00e9 le D<sup>r<\/sup>\u00a0Moriarty. Une des participantes \u00e0 la discussion sur cet essai, la D<sup>re<\/sup>\u00a0Karol Watson, de l\u2019\u00c9cole de m\u00e9decine David Geffen de l\u2019UCLA, \u00e0 Los Angeles, en Californie, a soulign\u00e9 l\u2019\u00ab\u00a0\u00e9norme difficult\u00e9\u00a0\u00bb que pose le traitement de cette population. \u00ab\u00a0Je trouve que la classe des anticorps monoclonaux dirig\u00e9s contre la PCSK9 est fascinante. Je crois qu\u2019elle pourra nous \u00eatre vraiment utile d\u00e8s que nous conna\u00eetrons les r\u00e9sultats des \u00e9tudes sur l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 \u00e0 long terme\u00a0\u00bb a-t-elle affirm\u00e9. Le D<sup>r<\/sup>\u00a0Moriarty a tenu \u00e0 ajouter que l\u2019essai ODYSSEY ALTERNATIVE est l\u2019une des 14\u00a0\u00e9tudes de Phase\u00a0III qui sont actuellement men\u00e9es sur l\u2019alirocumab. Une autre porte sur l\u2019issue du traitement chez plus de 20\u00a0000\u00a0sujets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><b> Chicago <\/b> \u2013 L\u2019essai ODYSSEY ALTERNATIVE a r\u00e9v\u00e9l\u00e9 qu\u2019au bout de 24 semaines de traitement, un inhibiteur de la PCSK9 avait abaiss\u00e9 les concentrations de cholest\u00e9rol des LDL (C-LDL) de fa\u00e7on significativement plus prononc\u00e9e qu\u2019un inhibiteur de l\u2019absorption du cholest\u00e9rol chez des patients ne tol\u00e9rant pas les statines et dont les concentrations \u00e9taient au d\u00e9part tr\u00e8s \u00e9lev\u00e9es. L\u2019inhibiteur de la PCSK9 a \u00e9t\u00e9 bien tol\u00e9r\u00e9 et a provoqu\u00e9 beaucoup moins d\u2019effets ind\u00e9sirables de nature musculo-squelettique qu\u2019une statine pendant le traitement.<\/p>\n","protected":false},"author":1,"featured_media":5381,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"tags":[409,425,301,523],"class_list":["post-5380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-2014-fr","tag-aha-fr","tag-cardiologie","tag-extract-fr","area_tag-cardiologie"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange\" \/>\n<meta property=\"og:description\" content=\"Chicago \u2013 L\u2019essai ODYSSEY ALTERNATIVE a r\u00e9v\u00e9l\u00e9 qu\u2019au bout de 24 semaines de traitement, un inhibiteur de la PCSK9 avait abaiss\u00e9 les concentrations de cholest\u00e9rol des LDL (C-LDL) de fa\u00e7on significativement plus prononc\u00e9e qu\u2019un inhibiteur de l\u2019absorption du cholest\u00e9rol chez des patients ne tol\u00e9rant pas les statines et dont les concentrations \u00e9taient au d\u00e9part tr\u00e8s \u00e9lev\u00e9es. L\u2019inhibiteur de la PCSK9 a \u00e9t\u00e9 bien tol\u00e9r\u00e9 et a provoqu\u00e9 beaucoup moins d\u2019effets ind\u00e9sirables de nature musculo-squelettique qu\u2019une statine pendant le traitement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Medical Xchange\" \/>\n<meta property=\"article:published_time\" content=\"2014-11-24T17:09:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-07T15:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"nuagelab\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"nuagelab\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/\"},\"author\":{\"name\":\"nuagelab\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\"},\"headline\":\"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e\",\"datePublished\":\"2014-11-24T17:09:26+00:00\",\"dateModified\":\"2021-09-07T15:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/\"},\"wordCount\":901,\"image\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG\",\"keywords\":[\"2014\",\"AHA\",\"cardiologie\",\"extract\"],\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/\",\"name\":\"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG\",\"datePublished\":\"2014-11-24T17:09:26+00:00\",\"dateModified\":\"2021-09-07T15:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG\",\"contentUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG\",\"width\":960,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/2014\\\/11\\\/24\\\/congres-scientifique-de-lamerican-heart-associat-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/\",\"name\":\"The Medical Xchange\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\",\"name\":\"nuagelab\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"caption\":\"nuagelab\"},\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/author\\\/nuagelab\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange","og_description":"Chicago \u2013 L\u2019essai ODYSSEY ALTERNATIVE a r\u00e9v\u00e9l\u00e9 qu\u2019au bout de 24 semaines de traitement, un inhibiteur de la PCSK9 avait abaiss\u00e9 les concentrations de cholest\u00e9rol des LDL (C-LDL) de fa\u00e7on significativement plus prononc\u00e9e qu\u2019un inhibiteur de l\u2019absorption du cholest\u00e9rol chez des patients ne tol\u00e9rant pas les statines et dont les concentrations \u00e9taient au d\u00e9part tr\u00e8s \u00e9lev\u00e9es. L\u2019inhibiteur de la PCSK9 a \u00e9t\u00e9 bien tol\u00e9r\u00e9 et a provoqu\u00e9 beaucoup moins d\u2019effets ind\u00e9sirables de nature musculo-squelettique qu\u2019une statine pendant le traitement.","og_url":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/","og_site_name":"The Medical Xchange","article_published_time":"2014-11-24T17:09:26+00:00","article_modified_time":"2021-09-07T15:34:00+00:00","og_image":[{"width":960,"height":720,"url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","type":"image\/png"}],"author":"nuagelab","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"nuagelab","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#article","isPartOf":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/"},"author":{"name":"nuagelab","@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b"},"headline":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e","datePublished":"2014-11-24T17:09:26+00:00","dateModified":"2021-09-07T15:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/"},"wordCount":901,"image":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#primaryimage"},"thumbnailUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","keywords":["2014","AHA","cardiologie","extract"],"articleSection":["Non classifi\u00e9(e)"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/","url":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/","name":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange","isPartOf":{"@id":"https:\/\/themedicalxchange.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#primaryimage"},"image":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#primaryimage"},"thumbnailUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","datePublished":"2014-11-24T17:09:26+00:00","dateModified":"2021-09-07T15:34:00+00:00","author":{"@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b"},"breadcrumb":{"@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#primaryimage","url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","contentUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","width":960,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/themedicalxchange.com\/en\/"},{"@type":"ListItem","position":2,"name":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e"}]},{"@type":"WebSite","@id":"https:\/\/themedicalxchange.com\/en\/#website","url":"https:\/\/themedicalxchange.com\/en\/","name":"The Medical Xchange","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/themedicalxchange.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b","name":"nuagelab","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","caption":"nuagelab"},"url":"https:\/\/themedicalxchange.com\/fr\/author\/nuagelab\/"}]}},"_links":{"self":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts\/5380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/comments?post=5380"}],"version-history":[{"count":0,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts\/5380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/media\/5381"}],"wp:attachment":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/media?parent=5380"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/tags?post=5380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}